| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Furner RL | |
| Brown RK | |||
| P433 | issue | 4-5 | |
| P304 | page(s) | 559-574 | |
| P577 | publication date | 1980-04-01 | |
| P1433 | published in | Cancer Treatment Reports | Q27710285 |
| P1476 | title | L-phenylalanine mustard (L-PAM): the first 25 years | |
| P478 | volume | 64 |
| Q33426795 | A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan |
| Q68286153 | A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma |
| Q34338552 | Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo |
| Q40167073 | Cellular pharmacokinetics of the phenylalanine mustards |
| Q40163156 | Clinical pharmacology in oncology. Recent advances |
| Q69443045 | Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors |
| Q34691861 | Effects of verapamil and alcohol on blood flow, melphalan uptake and cytotoxicity, in murine fibrosarcomas and human melanoma xenografts |
| Q34501199 | First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies |
| Q36765319 | In vitro and in vivo activity of melflufen (J1)in lymphoma |
| Q36604492 | Increased cancericidal activity of PTT.119, a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. I. In vitro cytotoxicity |
| Q42255432 | Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay. |
| Q41809290 | Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion |
| Q42371678 | Melflufen - a peptidase-potentiated alkylating agent in clinical trials |
| Q69656184 | Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma |
| Q52429822 | Renal function in the elimination of oral melphalan in patients with multiple myeloma. |
| Q39814611 | Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents |
| Q44816376 | Structural characterization of melphalan modified 2'-oligodeoxynucleotides by miniaturized LC-ES MS/MS. |
| Q69485761 | Studies on the mechanism of gastrointestinal absorption of melphalan and chlorambucil |
| Q36048084 | The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse |
| Q35991613 | The effect of systemic hyperthermia on melphalan pharmacokinetics in mice |
| Q34699444 | The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro |
| Q67969801 | The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma |
| Q49040235 | Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat. |
| Q69466560 | Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity |
Search more.